Unknown

Dataset Information

Pulmonary Nocardiosis in a Non-Small Cell Lung Cancer Patient Being Treated for Pembrolizumab-Associated Pneumonitis.


ABSTRACT:

Introduction

Immune-check-point inhibitors (ICIs) are established in the treatment of many malignancies. Many immune-related adverse events (irAEs) are well described; however, there is less information about opportunistic infections in cancer patients receiving ICIs.

Case presentation

We describe the case of a 62-year-old woman with non-small cell lung cancer, who relapsed after surgical resection and chemotherapy. She received 13 months of pembrolizumab, achieving stable disease, before presenting with suspected pneumonitis 2 weeks prior to departure for an international vacation. She was treated with high-dose corticosteroids and, shortly thereafter, developed severe nocardiosis, requiring venovenous extracorporeal membrane oxygenation and lengthy hospitalization.

Conc

SUBMITTER: Quartermain L 

PROVIDER: S-EPMC11501102 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature